Universe Pharmaceuticals INC (NASDAQ:UPC) Short Interest Update

Universe Pharmaceuticals INC (NASDAQ:UPC) was the recipient of a significant increase in short interest in August. As of August 14th, there was short interest totaling 35,401 shares, an increase of 454.7% from the July 30th total of 6,382 shares. Currently, 1.7% of the company’s stock are short sold. Based on an average trading volume of 2,816,444 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Universe Pharmaceuticals has a consensus rating of “Sell”.

Universe Pharmaceuticals Stock Down 6.2%

Shares of NASDAQ UPC opened at $5.03 on Wednesday. The business has a 50-day moving average of $4.95 and a two-hundred day moving average of $3.65. Universe Pharmaceuticals has a 1 year low of $2.00 and a 1 year high of $17.96. The company has a quick ratio of 3.90, a current ratio of 4.05 and a debt-to-equity ratio of 0.04.

Universe Pharmaceuticals (NASDAQ:UPC) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($1.38) EPS for the quarter. The firm had revenue of $4.52 million during the quarter.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.